RDI Initiates Coverage:

Conatus Pharmaceuticals Inc. https://ub.rdinvesting.com/news/?ticker=CNAT

MannKind Corporation https://ub.rdinvesting.com/news/?ticker=MNKD

Conatus Pharmaceuticals dropped 2.53% to close at $5.77 on Friday. The stock traded between $5.61 and $6.43 on volume of 4.21 million shares traded. The drop in price comes after the company announced it will be making presentations during the 1st week of April – at the H.C. Wainwright NASH Investor Conference on Monday, April 3rd, and at the 16th Annual Needham Healthcare Conference on Tuesday, April 4th. In its latest financial report of March 15th, the company announced it had entered into an exclusive license agreement with Novartis for the global development and commercialization of emricasan, its chronic liver disease drug.

Conatus Pharmaceuticals reported a net loss $29.7 million loss for the full year of 2016, compared to net loss of $24.15 million reported in the year 2015. The company reported R&D expenses increased to a total of $20.3 million for the year 2016, compared to $16.3 million in 2015

Access RDI’s Conatus Pharmaceuticals Research Report at:https://ub.rdinvesting.com/news/?ticker=CNAT

MannKind declined 0.67% to close at $1.48 on Friday. The stock traded between $1.45 and $1.64 on volume of 3.13 million shares traded. The stock has seen a 2017 high of $3.56 per share and a 52 week high of $10.15 per share. On March 15th, the company reported total revenues of $12.4 million for the fourth quarter of 2016. MannKind’s main product Afrezza, an inhaler-based insulin treatment, accounted for $1.3 million in revenues. Deferred net revenues from Afrezza were $1.7 million in the fourth quarter of 2016.

On March 8th, MannKind Corporation and Bella & Elle Media LLC announced MannKind’s sponsorship of “Reversed,” a production series aimed at educating the show’s participants and viewing audience about the effects of poorly managed diabetes and its impact on their lives. “Reversed” will air on Discovery Life Channel in the summer of 2017.

Access RDI’s MannKind Research Report at: https://ub.rdinvesting.com/news/?ticker=MNKD

Our Actionable Research on Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) and MannKind Corporation (NASDAQ: MNKD) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com